World-first stem cell therapy trial

A world-first safety trial is underway examining amniotic stem cells as therapy for acute stroke. The study is a partnership between La Trobe University, Monash Health and Hudson Institute of Medical Research.

When 67-year-old Kevin Baird arrived at Monash Medical Centre in February after having a stroke, he was no longer able to receive standard stroke treatments. Unfortunately for Kevin, the stroke had left him with significant speech problems and upper-limb weakness.

“Before the treatment they asked me if I could raise my hands,” Mr Baird said. “I thought ‘Of course I can raise my hands, just watch.’

“But then when I actually tried to, I couldn’t. I was only speaking in a mumble as well.”

“About day after I received the treatment as part of the trial, and I started to notice progress,” Mr Baird said. “And I’ve come on in leaps and bounds since then. I believe it helped tremendously.”

“Stroke is the second-leading cause of death globally, and leaves a huge number of people with significant disability,” Prof Ma said.

“We have fantastic treatments for stroke such as endovascular clot retrieval and also clot-busting medications, but we know that for too many patients even these treatments are not enough. A significant number of patients may not have access to these therapies or they’re not possible due to circumstances.”

Professor Chris Sobey from La Trobe University and Associate Professor Rebecca Lim from Hudson Institute of Medical Research had been working with Associate Professor Ma and Professor Thanh Phan, Head of Stroke at Monash Health, to explore amniotic stem cells as a possible treatment for acute ischemic stroke patients.

Associate Professor Lim, Head of Amnion Cell Research at Hudson, said that amniotic stem cell therapies have, theoretically, a lot of advantages.

“These cells carry no immunological rejection risk,” Associate Professor Lim said. “They don’t have to be matched and cultured and surgically injected as some other modes of stem cell therapy require.”

Preliminary research that took place prior to this trial suggested that the stem cells, delivered intravenously, travel through the body but congregate where they’re actually needed – around damaged brain tissue.

For Professor Sobey, the Co-Director of La Trobe’s Research Centre for Cardiovascular Biology and Disease, this versatility made them ideal for acute stroke situations, where time is critical.

“After a stroke the key is working to save neurons before they die. ‘Time is brain’ is the catchcry, so by rapidly treating a stroke and saving brain tissue, we reduce lasting damage which can cause disability,” Professor Sobey said.

While the purpose of the trial is to establish the treatment’s safety, Mr Baird has had a remarkable recovery after the treatment.

After experiencing significant speech problems and arm weakness, Mr Baird now has some very mild facial droop, and MRIs show there is no further damage to his brain tissue beyond the initial stroke.

The current trial is not examining the efficacy of the treatment.

“We need to be very cautious and establish safety, first-and-foremost. That is the current trial’s focus,” said Associate Professor Lim. “However we are extremely encouraged by the fact that Mr Baird’s brain tissue has shown such good outcomes.”

Professor Sobey agreed, saying that Mr Baird’s case meant their trial was attracting attention from major stroke centres around the world.

“It is a long process, but we are hopeful that this collaboration can contribute to the next great breakthrough in global stroke care, and prevent ongoing disability for patients.”

“I commend these researchers for searching out new ways to protect us against the too often devastating impact of stroke and look forward to seeing where this promising research leads,” Victorian Minister for Health Jenny Mikakos said.

“Victoria is a world leader in ground-breaking health and medical research and is home to some of the world’s best clinicians, scientists and researchers. We’re leading the way in breakthrough discoveries to fast-track new treatments and save the lives of more people at home and around the world.”

Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don't put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources.
It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!

Mirage News . All timestamps on this site are AEST/AEDT and all times in the articles are local times unless indicated otherwise.

All trademarks and rights are owned by their respective owners. All content is used for news reporting purposes.
For news reporting purposes, we rely on fair use (fair dealing) [1] [2]for textual and media content to keep the public informed on the developments. If you are a person mentioned in the story or you are a copyright holder and believe that any content should be removed, revised or taken down, please contact us. View the disclaimer page here